In one preclinical study, intratumoral injection of the TLR9 agonist IMO-2125 in combination with systemic anti-PD-1 increased tumor-infiltrating dendritic and T cells in tumor and lymph nodes, resulting in local and distant antitumor effects in a low immunogenic murine PDAC subtype (FC1242) [98]. This evidence concerns the gene TLR9 and neoplasm.